ATE532515T1 - Stabile laquinimod-zubereitungen - Google Patents

Stabile laquinimod-zubereitungen

Info

Publication number
ATE532515T1
ATE532515T1 AT07809468T AT07809468T ATE532515T1 AT E532515 T1 ATE532515 T1 AT E532515T1 AT 07809468 T AT07809468 T AT 07809468T AT 07809468 T AT07809468 T AT 07809468T AT E532515 T1 ATE532515 T1 AT E532515T1
Authority
AT
Austria
Prior art keywords
preparations
stable
stable laquinimod
laquinimod preparations
laquinimod
Prior art date
Application number
AT07809468T
Other languages
English (en)
Inventor
Shulamit Patashnik
Daniella Licht
Adrian Gilbert
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Application granted granted Critical
Publication of ATE532515T1 publication Critical patent/ATE532515T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Composite Materials (AREA)
  • Mechanical Engineering (AREA)
AT07809468T 2006-06-12 2007-06-12 Stabile laquinimod-zubereitungen ATE532515T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81324706P 2006-06-12 2006-06-12
PCT/US2007/013721 WO2007146248A2 (en) 2006-06-12 2007-06-12 Stable laquinimod preparations

Publications (1)

Publication Number Publication Date
ATE532515T1 true ATE532515T1 (de) 2011-11-15

Family

ID=38832466

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07809468T ATE532515T1 (de) 2006-06-12 2007-06-12 Stabile laquinimod-zubereitungen

Country Status (27)

Country Link
US (3) US7989473B2 (de)
EP (1) EP2035001B1 (de)
JP (1) JP5226678B2 (de)
KR (4) KR20150065951A (de)
CN (1) CN101466379B (de)
AR (1) AR061348A1 (de)
AT (1) ATE532515T1 (de)
AU (1) AU2007258366B2 (de)
BR (1) BRPI0713694A2 (de)
CA (2) CA2899472C (de)
CY (1) CY1113003T1 (de)
DK (1) DK2035001T3 (de)
EA (1) EA018031B1 (de)
ES (1) ES2377149T3 (de)
HR (1) HRP20120093T1 (de)
IL (1) IL195724A (de)
MX (1) MX2008015808A (de)
NO (1) NO342485B1 (de)
NZ (1) NZ573846A (de)
PL (1) PL2035001T3 (de)
PT (1) PT2035001E (de)
RS (1) RS52169B (de)
SI (1) SI2035001T1 (de)
TW (1) TWI400073B (de)
UA (1) UA96449C2 (de)
WO (1) WO2007146248A2 (de)
ZA (1) ZA200810790B (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314124B2 (en) 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
NZ567088A (en) 2005-10-19 2012-06-29 Teva Pharma Crystals of laquinimod sodium, and process for the manufacture thereof
KR20150065951A (ko) 2006-06-12 2015-06-15 테바 파마슈티컬 인더스트리즈 리미티드 안정한 라퀴니모드 제제
EP2234485B1 (de) 2007-12-20 2013-11-13 Teva Pharmaceutical Industries, Ltd. Stabile laquinimod-präparate
KR20110048571A (ko) * 2008-09-03 2011-05-11 테바 파마슈티컬 인더스트리즈 리미티드 면역 기능을 지닌 ２―옥소―１,２―다이하이드로―퀴놀린 조절제
DE102010048788A1 (de) 2009-02-13 2011-05-19 Amw Gmbh Transdermales System mit Immunmodulator
DE102009008851A1 (de) 2009-02-13 2010-08-19 Amw Gmbh Transdermales System mit Immunmodulator
JP2012530701A (ja) * 2009-06-19 2012-12-06 テバ ファーマシューティカル インダストリーズ リミティド 多発性硬化症のラキニモドでの治療
PL2458992T3 (pl) * 2009-07-30 2016-07-29 Teva Pharma Leczenie choroby Leśniowskiego-Crohna z użyciem lakwinimodu
WO2011019375A1 (en) 2009-08-10 2011-02-17 Teva Pharmaceutical Industries Ltd. Treatment of bdnf-related disorders using laquinimod
DE102010026879A1 (de) 2010-02-11 2011-08-11 AMW GmbH, 83627 Transdermales System mit Immunmodulator
CA2791711A1 (en) * 2010-03-03 2011-09-09 Teva Pharmaceutical Industries Ltd. Treatment of lupus arthritis using laquinimod
SG183512A1 (en) * 2010-03-03 2012-09-27 Teva Pharma Treatment of lupus nephritis using laquinimod
DK2542079T3 (da) * 2010-03-03 2014-08-25 Teva Pharma Behandling af reumatoid artritis med en kombination af laquinimod og methotrexat
WO2012006538A1 (en) 2010-07-09 2012-01-12 Teva Pharmaceutical Industries Ltd. Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
EP2590653A4 (de) 2010-07-09 2014-01-01 Teva Pharma 5-chlor-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydrochinolin-3-carboxamid, salze davon und anwendungen dafür
AU2011338647A1 (en) * 2010-12-07 2013-07-04 Teva Pharmaceutical Industries Ltd. Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
AU2012286701A1 (en) * 2011-07-28 2014-03-06 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and interferon-beta
IN2014MN00333A (de) * 2011-07-28 2015-09-25 Teva Pharma
CA2851525A1 (en) * 2011-10-12 2013-04-18 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod
CN104093310A (zh) 2012-02-03 2014-10-08 泰华制药工业有限公司 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途
JP6215238B2 (ja) 2012-02-16 2017-10-18 テバ ファーマシューティカル インダストリーズ リミティド Ｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４，５−ジ−ヒドロキシ−１−メチル−２−オキソ−３−キノリンカルボキサミド、その製剤、および使用
US20130259856A1 (en) 2012-03-27 2013-10-03 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
US20130345257A1 (en) * 2012-06-26 2013-12-26 The Regents Of The University Of California Composition for lupus nephritis and methods of making and using the same
AR091706A1 (es) * 2012-07-11 2015-02-25 Teva Pharma Formulaciones de laquinimod sin agentes alcalinizantes
TW201410243A (zh) * 2012-08-13 2014-03-16 Teva Pharma 用於治療大麻素受體型１（ｃｂ１）媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
TW201410244A (zh) * 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
EP2916915A4 (de) * 2012-11-07 2016-06-22 Teva Pharma Aminsalze von laquinimod
BR112015019564A2 (pt) * 2013-02-15 2017-07-18 Teva Pharma tratamento de esclerose múltipla com laquinimod
US20160046582A1 (en) 2013-03-14 2016-02-18 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
US20160038435A1 (en) 2013-03-14 2016-02-11 Teva Pharmaceutical Industries Ltd. Transdermal formulations of laquinimod
US20150094332A1 (en) * 2013-09-27 2015-04-02 Teva Pharmaceutical Industries, Ltd. Laquinimod Combination Therapy For Treatment Of Multiple Sclerosis
CA2933380A1 (en) * 2013-12-20 2015-06-25 Esther Lukasiewicz Hagai Use of laquinimod to delay huntington's disease progression
HK1225969A1 (zh) * 2014-01-17 2017-09-22 Teva Pharmaceutical Industries Ltd 利用低剂量的拉喹莫德治疗克隆氏病
WO2015168103A1 (en) 2014-04-29 2015-11-05 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
CN110193014B (zh) * 2019-06-06 2021-05-11 温州医科大学 一种注射用拉喹莫德胶束冻干制剂及制备方法、拉喹莫德注射制剂

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3024257A (en) * 1961-04-10 1962-03-06 Frosst & Co Charles E Stable preparations of alkali metal salts of estrone sulfate
FR2340735A1 (fr) * 1976-02-11 1977-09-09 Roussel Uclaf Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
DE3437232A1 (de) * 1984-10-10 1986-04-17 Mack Chem Pharm Stabilisierte injektionsloesungen von piroxicam
SE8902076D0 (sv) 1989-06-09 1989-06-09 Pharmacia Ab Derivatives of quinoline-3-carboxanilide
HUT60458A (en) 1991-02-01 1992-09-28 Sandoz Ag Process for producing benzyloxyphenyl derivatives and pharmaceutical compositions comprising same
US5540934A (en) * 1994-06-22 1996-07-30 Touitou; Elka Compositions for applying active substances to or through the skin
CH687615A5 (de) * 1994-09-07 1997-01-15 R W Johnson Pharmaceutical Res Tropen-Verpackung.
US5912349A (en) * 1997-01-31 1999-06-15 Pharmacia & Upjohn Company Process for the preparation of roquinimex
US20030124187A1 (en) * 1997-02-14 2003-07-03 Smithkline Beecham Laboratoires Pharmaceutiques, Pharmaceutical formulations comprising amoxycillin and clavulanate
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE9801474D0 (sv) 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
SE9802549D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
SE9802550D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6133285A (en) * 1998-07-15 2000-10-17 Active Biotech Ab Quinoline derivatives
US6121287A (en) * 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives
ES2246238T3 (es) 1999-06-07 2006-02-16 Altana Pharma Ag Nueva preparacion y forma de administracion que comprende un inhibidor de las bombas de protones labil en medio acido.
PL199781B1 (pl) * 1999-10-25 2008-10-31 Active Biotech Ab Nowe związki pochodne chinoliny, zastosowanie związków pochodnych chinoliny, zawierające je kompozycje farmaceutyczne i sposób ich wytwarzania
SE0002320D0 (sv) 1999-10-25 2000-06-21 Active Biotech Ab Malignant tumors
JP2002031610A (ja) 2000-07-14 2002-01-31 Ajinomoto Co Inc 生体分子複合体の界面残基を同定する方法
US6307050B1 (en) 2000-08-29 2001-10-23 R. T. Alamo Venture I Llc Method of synthesizing flosequinan from 4-fluoroanthranilic acid
US6802422B2 (en) * 2000-12-12 2004-10-12 Multi-Comp, Inc. Sealed blister assembly
US6706733B2 (en) 2001-05-08 2004-03-16 Dainippon Ink And Chemicals, Inc. Quinolinone derivative formulation and its production method
US20030119826A1 (en) * 2001-09-24 2003-06-26 Pharmacia Corporation Neuroprotective treatment methods using selective iNOS inhibitors
US6875869B2 (en) * 2002-06-12 2005-04-05 Active Biotech Ab Process for the manufacture of quinoline derivatives
US7560557B2 (en) * 2002-06-12 2009-07-14 Active Biotech Ag Process for the manufacture of quinoline derivatives
SE0201778D0 (sv) * 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
US8980870B2 (en) * 2002-09-24 2015-03-17 Boehringer Ingelheim International Gmbh Solid telmisartan pharmaceutical formulations
US7820145B2 (en) * 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US7790197B2 (en) * 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
US20060188568A1 (en) * 2003-10-30 2006-08-24 Lupin Limited Stable formulations of ace inhibitors and methods for preparation thereof
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
US8314124B2 (en) * 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
NZ567088A (en) * 2005-10-19 2012-06-29 Teva Pharma Crystals of laquinimod sodium, and process for the manufacture thereof
KR20150065951A (ko) 2006-06-12 2015-06-15 테바 파마슈티컬 인더스트리즈 리미티드 안정한 라퀴니모드 제제
US20080087929A1 (en) * 2006-10-11 2008-04-17 Infineon Technologies Ag Static random access memory with thin oxide capacitor
EP2234485B1 (de) 2007-12-20 2013-11-13 Teva Pharmaceutical Industries, Ltd. Stabile laquinimod-präparate
KR20110048571A (ko) 2008-09-03 2011-05-11 테바 파마슈티컬 인더스트리즈 리미티드 면역 기능을 지닌 ２―옥소―１,２―다이하이드로―퀴놀린 조절제
JP2012530701A (ja) 2009-06-19 2012-12-06 テバ ファーマシューティカル インダストリーズ リミティド 多発性硬化症のラキニモドでの治療
PL2458992T3 (pl) 2009-07-30 2016-07-29 Teva Pharma Leczenie choroby Leśniowskiego-Crohna z użyciem lakwinimodu
WO2011019375A1 (en) 2009-08-10 2011-02-17 Teva Pharmaceutical Industries Ltd. Treatment of bdnf-related disorders using laquinimod
CA2791711A1 (en) 2010-03-03 2011-09-09 Teva Pharmaceutical Industries Ltd. Treatment of lupus arthritis using laquinimod
DK2542079T3 (da) 2010-03-03 2014-08-25 Teva Pharma Behandling af reumatoid artritis med en kombination af laquinimod og methotrexat
SG183512A1 (en) 2010-03-03 2012-09-27 Teva Pharma Treatment of lupus nephritis using laquinimod
EP2590653A4 (de) 2010-07-09 2014-01-01 Teva Pharma 5-chlor-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydrochinolin-3-carboxamid, salze davon und anwendungen dafür
WO2012006538A1 (en) 2010-07-09 2012-01-12 Teva Pharmaceutical Industries Ltd. Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof

Also Published As

Publication number Publication date
AU2007258366B2 (en) 2012-10-25
AR061348A1 (es) 2008-08-20
NO20090175L (no) 2009-03-11
KR20090017694A (ko) 2009-02-18
US7989473B2 (en) 2011-08-02
CY1113003T1 (el) 2016-04-13
EP2035001A2 (de) 2009-03-18
KR101495327B1 (ko) 2015-02-24
UA96449C2 (en) 2011-11-10
HK1121971A1 (en) 2009-05-08
US20110251235A1 (en) 2011-10-13
KR20140091778A (ko) 2014-07-22
US8383645B2 (en) 2013-02-26
EP2035001A4 (de) 2009-09-23
EP2035001B1 (de) 2011-11-09
CA2899472A1 (en) 2007-12-21
TW200815006A (en) 2008-04-01
CA2654982C (en) 2015-11-10
JP5226678B2 (ja) 2013-07-03
KR20160013273A (ko) 2016-02-03
CA2654982A1 (en) 2007-12-21
CN101466379B (zh) 2012-10-31
RS52169B (sr) 2012-08-31
JP2009539984A (ja) 2009-11-19
EA018031B1 (ru) 2013-05-30
MX2008015808A (es) 2009-02-17
HRP20120093T1 (hr) 2012-03-31
SI2035001T1 (sl) 2012-03-30
NO342485B1 (no) 2018-05-28
IL195724A0 (en) 2009-09-01
US20070293537A1 (en) 2007-12-20
IL195724A (en) 2015-09-24
CN101466379A (zh) 2009-06-24
BRPI0713694A2 (pt) 2012-10-30
PT2035001E (pt) 2012-02-06
AU2007258366A1 (en) 2007-12-21
KR20150065951A (ko) 2015-06-15
WO2007146248A2 (en) 2007-12-21
ES2377149T3 (es) 2012-03-22
TWI400073B (zh) 2013-07-01
PL2035001T3 (pl) 2012-05-31
EA200870599A1 (ru) 2009-06-30
ZA200810790B (en) 2010-03-31
NZ573846A (en) 2012-01-12
DK2035001T3 (da) 2012-02-27
US20120302600A1 (en) 2012-11-29
CA2899472C (en) 2019-04-30
WO2007146248A3 (en) 2008-12-24

Similar Documents

Publication Publication Date Title
DK2035001T3 (da) Stabile laquinimod-tilberedninger
DK2234485T3 (da) Stabile laquinimod-præparater
FIC20190019I1 (fi) Flupyradifuroni
DK2068886T3 (da) Lipidholdige præparater
ATE443753T1 (de) Nuancierungsmittel
ATE475662T1 (de) Dihydropyrazolopyrimidinonderivate
ATE483711T1 (de) Spiroindolinonderivate
ATE469905T1 (de) Pyridopyrimidinonderivate
ATE512135T1 (de) Spiroindolinonderivate
DE602007010981D1 (de) Cycloalkylaminsubstituierte isochinolin- und isochinolinonderivate
DK2046826T3 (da) Exendin-fusionsproteiner
DK2035394T3 (da) 2-pyrazincarboxamidderivater
DK1962886T4 (da) Stabile proteinformuleringer
DK2089364T3 (da) Pyridinonforbindelser
AT504580A3 (de) Scan-einrichtung
ATE434613T1 (de) Isochinolinderivate
BRPI0717939A2 (pt) Aminometil-4-imidazóis
FI20060389L (fi) Sensori
EP2065801A4 (de) Emulator
ATE544764T1 (de) 5-hydroxymethyloxazolidin-2-onderivate
DE502006006067D1 (de) Ng
FR2902879B1 (fr) Rheometre orthogonal
FR2897662B1 (fr) Joint homocinetique
FR2907178B1 (fr) Joint homocinetique
DE112007003392A5 (de) Gelenkbeschlag

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2035001

Country of ref document: EP